Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Mute reaction to AstraZeneca vaccine is no reason to lose optimism

Positive vaccine news flow for the third successive Monday appears to be eliciting increasingly weaker share price reactions.
For example, despite good news on 23 November from AstraZeneca (AZN) and Oxford University that vaccine candidate AD1222 was 70% effective in preventing Covid-19, markets barely moved that day.
This vaccine is thought to be cheaper and easier to distribute than competing vaccines, but AstraZeneca’s shares fell 3% on the day of the announcement as investors clearly expected more from the trial result.
The same pattern was seen last week after US firm Moderna reported that its vaccine was 95.5% effective at preventing Covid-19. Stock markets initially gained 2% to 3% before easing back, compared to the near-5% gain for the FTSE All-Share upon the Pfizer news.
The day after the AstraZeneca news proved to be better for markets, led by investors bidding up stocks in travel firms on hopes of earnings recovery, oil stocks rising on a stronger oil price, and Donald Trump accepting the US presidency transition to Joe Biden must begin, thus implying a smoother than expected handover.
There was a continuation of recent trends whereby investors sold down higher quality companies which have done well this year, in favour of buying the ones that have been bombed-out.
Pubs and leisure stocks got a shot in the arm after Prime Minister Boris Johnson said England would return to localised restrictions once the current lockdown ends on 2 December.
While pubs in tier three will only be allowed to provide a takeaway service those in the second tier which serve food will be allowed to fully reopen. Non-essential shops and gyms will reopen as will grass roots sports.
The downside is that leisure companies may not benefit too much if large parts of the country are put in tier three – we’ll find out on 26 November.
It wasn’t just stock markets which have received a boost in recent weeks from the welcome arrival of a vaccine. The riskier end of the bond market has also seen a significant uptick in investor interest.
Cruise ship company Carnival (CCC) was in demand, increasing the size of its unsecured private bond offering by an additional $650 million to an aggregate $1.95 billion.
Global cinema group Cineworld (CINE) secured an additional $450 million of debt but had to sweeten the deal by issuing warrants equivalent to around 10% of the company’s share capital.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Editor's View
Feature
First-time Investor
Great Ideas
- Boston Scientific has big potential to get back on top in 2021
- Buy this trust to access cut-price quality names
- Take advantage of share price pullback to buy more Softcat stock
- Strong trading could lead to more generous dividends for Somero
- Reasons to be more optimistic on AG Barr
- Odyssean Investment Trust sails in with swift 17.4% return
Investment Trusts
Money Matters
News
- Sunak pledges increased spending on jobs, housing and infrastructure
- Germany’s blue-chip index gets big overhaul after Wirecard scandal
- Controversial fast-track funding rule scrapped
- Blue Prism eyes US listing to help narrow valuation gap
- Worst of dividend cuts ‘now over’ says Janus Henderson
- Video game platform Roblox could see blockbuster market debut
- Mute reaction to AstraZeneca vaccine is no reason to lose optimism
- UK ‘green revolution’ could be great for investors